25
Jul
Zydus Lifesciences on Monday, July 22, said it has received approval from the Mexico regulator COFEPRIS to market Bhava, which will be used to treat various cancers.Bhava is a Bevacizumab biosimilar and it will be marketed in strengths of 100 mg/4ml and 400 mg/16ml. It is used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, advanced and/or metastatic renal cell carcinoma and ovarian cancer, Zydus Life said in a statement. It added that as per a WHO 2020 report, of all the cancer cases reported in Mexico, breast, prostate, colorectal and thyroid…